Code

Code Biotherapeutics is a biotechnology company pioneering the development of targeted, non-viral genetic medicines to treat serious and life-threatening genetic diseases. The company’s core technology is the proprietary 3DNA® platform, a multivalent synthetic DNA delivery system engineered to overcome the limitations of traditional viral vectors, such as immunogenicity, payload size restrictions, and the inability to re-dose patients. Code Bio is advancing an internal pipeline focused on Duchenne Muscular Dystrophy (DMD) and Type 1 Diabetes (T1D), while also leveraging its platform through strategic partnerships. Notably, the company has a multi-program collaboration with Takeda worth up to $2 billion to develop gene therapies for rare liver and central nervous system diseases. Headquartered in Greater Philadelphia, Code Bio is backed by a syndicate of top-tier life science investors including Northpond Ventures, Amgen Ventures, and Takeda Ventures.